# Tetragon Partners GP Ltd

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1515070. Source: https://holderbook.com/funds/1515070-tetragon-partners-gp-ltd/

- Reported value: $635.1M
- Positions: 36
- Weight of the ten largest: 74.1%
- Filed: 2026-08-13

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| UIPATH INC | [PATH](https://holderbook.com/stocks/PATH/) | $336.4M | 30,950,000 | 53.0% | 18 |
| KOLIBRI GLOBAL ENERGY INC | [KGEI](https://holderbook.com/stocks/KGEI/) | $33.8M | 6,834,504 | 5.3% | 11 |
| AUTOLUS THERAPEUTICS LTD | [AUTL](https://holderbook.com/stocks/AUTL/) | $15.2M | 9,500,000 | 2.4% | 31 |
| LYFT INC | [LYFT](https://holderbook.com/stocks/LYFT/) | $14.6M | 1,000,000 | 2.3% | 19 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $13.5M | 286,990 | 2.1% | 2 |
| WORKIVA INC | [WK](https://holderbook.com/stocks/WK/) | $12.1M | 250,000 | 1.9% | 5 |
| SILENCE THERAPEUTICS PLC | [SLN](https://holderbook.com/stocks/SLN/) | $11.7M | 764,256 | 1.8% | 3 |
| SPRINKLR INC | [CXM](https://holderbook.com/stocks/CXM/) | $11.4M | 2,200,000 | 1.8% | 18 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $11.2M | 203,543 | 1.8% | 4 |
| ALKAMI TECHNOLOGY INC | [ALKT](https://holderbook.com/stocks/ALKT/) | $10.9M | 600,284 | 1.7% | 1 |
| CELLDEX THERAPEUTICS INC NEW | [CLDX](https://holderbook.com/stocks/CLDX/) | $10.8M | 290,441 | 1.7% | 7 |
| RELAY THERAPEUTICS INC | [RLAY](https://holderbook.com/stocks/RLAY/) | $10.7M | 570,311 | 1.7% | 2 |
| ARROWHEAD PHARMACEUTICALS IN | [ARWR](https://holderbook.com/stocks/ARWR/) | $10.6M | 130,484 | 1.7% | 4 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $10.2M | 295,627 | 1.6% | 6 |
| ALKERMES PLC | [ALKS](https://holderbook.com/stocks/ALKS/) | $10.0M | 189,979 | 1.6% | 5 |
| IMMUNOVANT INC | [IMVT](https://holderbook.com/stocks/IMVT/) | $9.9M | 255,934 | 1.6% | 6 |
| AGIOS PHARMACEUTICALS INC | [AGIO](https://holderbook.com/stocks/AGIO/) | $9.5M | 205,579 | 1.5% | 3 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $8.6M | 0 | 1.3% | 7 |
| DYNE THERAPEUTICS INC | [DYN](https://holderbook.com/stocks/DYN/) | $7.9M | 356,657 | 1.2% | 5 |
| IONIS PHARMACEUTICALS INC | [IONS](https://holderbook.com/stocks/IONS/) | $7.7M | 97,173 | 1.2% | 2 |
| HARMONY BIOSCIENCES HLDGS IN | [HRMY](https://holderbook.com/stocks/HRMY/) | $7.3M | 201,036 | 1.2% | 3 |
| KRYSTAL BIOTECH INC | [KRYS](https://holderbook.com/stocks/KRYS/) | $7.3M | 19,668 | 1.2% | 4 |
| ANNEXON INC | [ANNX](https://holderbook.com/stocks/ANNX/) | $7.1M | 1,242,455 | 1.1% | 9 |
| CELCUITY INC | [CELC](https://holderbook.com/stocks/CELC/) | $6.7M | 64,110 | 1.1% | 1 |
| WARNER BROS DISCOVERY INC | [WBD](https://holderbook.com/stocks/WBD/) | $6.7M | 250,000 | 1.0% | 2 |
| NEKTAR THERAPEUTICS | [NKTR](https://holderbook.com/stocks/NKTR/) | $6.1M | 86,996 | 1.0% | 3 |
| AMYLYX PHARMACEUTICALS INC | [AMLX](https://holderbook.com/stocks/AMLX/) | $5.5M | 297,926 | 0.9% | 5 |
| ACADIA PHARMACEUTICALS INC | [ACAD](https://holderbook.com/stocks/ACAD/) | $4.2M | 167,875 | 0.7% | 2 |
| ULTRAGENYX PHARMACEUTICAL IN | [RARE](https://holderbook.com/stocks/RARE/) | $3.3M | 0 | 0.5% | 2 |
| CUE BIOPHARMA INC | [CUE](https://holderbook.com/stocks/CUE/) | $3.0M | 93,819 | 0.5% | 1 |
| SNOWFLAKE INC | [SNOW](https://holderbook.com/stocks/SNOW/) | $2.5M | 10,000 | 0.4% | 19 |
| KARYOPHARM THERAPEUTICS INC | [KPTI](https://holderbook.com/stocks/KPTI/) | $2.4M | 0 | 0.4% | 2 |
| ACLARIS THERAPEUTICS INC | [ACRS](https://holderbook.com/stocks/ACRS/) | $2.1M | 400,000 | 0.3% | 1 |
| TECTONIC THERAPEUTIC INC | [TECX](https://holderbook.com/stocks/TECX/) | $1.6M | 46,516 | 0.3% | 2 |
| MONTE ROSA THERAPEUTICS INC | [GLUE](https://holderbook.com/stocks/GLUE/) | $1.4M | 56,052 | 0.2% | 1 |
| TENAX THERAPEUTICS INC | [TENX](https://holderbook.com/stocks/TENX/) | $1.1M | 0 | 0.2% | 1 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +5.4% | +14.8% | -9.5% | 98% |
| Q1 2026 | -20.5% | -4.6% | -15.9% | 99% |
| Q1 2025 | -6.5% | -4.6% | -2.0% | 60% |
| Q4 2024 | +8.5% | +2.1% | +6.3% | 64% |
| Q1 2024 | +4.5% | +10.0% | -5.6% | 65% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $635.1M | 36 |
| Q1 2026 | $515.1M | 34 |
| Q4 2025 | $474.3M | 28 |
| Q3 2025 | $747.6M | 43 |
| Q2 2025 | $620.8M | 36 |
| Q1 2025 | $438.2M | 30 |
| Q4 2024 | $391.4M | 26 |
| Q3 2024 | $354.5M | 23 |
| Q2 2024 | $400.9M | 27 |
| Q1 2024 | $441.5M | 29 |
| Q4 2023 | $415.3M | 31 |
| Q3 2023 | $548.3M | 46 |